We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+24.82%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$177M
AUM Growth
+$16.5M
Cap. Flow
-$12.9M
Cap. Flow %
-7.32%
Top 10 Hldgs %
99.72%
Holding
12
New
1
Increased
1
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
SNNA
Sienna Biopharmaceuticals, Inc.
SNNA
+$16.7M
2
CBAY
Cymabay Therapeutics
CBAY
+$1.69M

Top Sells

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$13.2M
2
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$11.9M
3
JUNO
Juno Therapeutics, Inc.
JUNO
+$5.28M
4
PVLA
Palvella Therapeutics
PVLA
+$871K

Sector Composition

Rank Sector Weight
1 Healthcare 72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
1
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$65.3M 36.93%
2,600,410
– –
JUNO
2
DELISTED
Juno Therapeutics, Inc.
JUNO
$48.2M 27.27%
1,074,612
-154,900
-13% -$5.28M
KYNB
3
Kyntra Bio
KYNB
$28.5M
$16.9M 9.57%
12,574
-12,526
-50% -$13.2M
SNNA
4
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$16.9M 9.55%
+758,610
New +$16.7M
JNCE
5
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$9.03M 5.11%
579,650
– –
PVLA
6
Palvella Therapeutics
PVLA
$1.98B
$6.93M 3.92%
15,051
-2,040
-12% -$871K
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$4.45M 2.51%
551,477
+250,000
+83% +$1.69M
EGLT
8
DELISTED
Egalet Corporation
EGLT
$3.7M 2.09%
2,889,926
– –
CDTX
9
DELISTED
Cidara Therapeutics
CDTX
$3.6M 2.04%
22,248
– –
DRNA
10
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.28M 0.73%
223,457
– –
EPIX
11
DELISTED
ESSA Pharma
EPIX
$492K 0.28%
84,848
– –
NBRV
12
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-4,556
Closed -$11.9M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q3 2017 Portfolio in Review

As of Q3 2017, Omega Fund Management held 12 positions worth $177M, up 10% from $160M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Omega Fund Management withdrew a net $12.9M in Q3 2017, closing 1 position and reducing 3 holdings. Its most notable exit was Nabriva Therapeutics plc Ordinary Shares Ireland, an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 77% a quarter earlier.

Against the trend, Omega Fund Management opened a new position in Sienna Biopharmaceuticals, Inc. worth $16.9M.

  • Omega Fund Management's largest Q3 2017 buy was Sienna Biopharmaceuticals, Inc.: 758,610 shares worth $16.9M.
  • Omega Fund Management added most to Cymabay Therapeutics in Q3 2017, an estimated $1.69M increase.
  • Omega Fund Management's biggest Q3 2017 reduction was Kyntra Bio, cutting an estimated $13.2M.
  • Omega Fund Management fully exited Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2017, selling an estimated $11.9M.
  • Omega Fund Management's ten largest holdings make up 100% of its $177M portfolio in Q3 2017.
  • Omega Fund Management opened 1 new position and closed 1 in Q3 2017.
  • Omega Fund Management's portfolio value rose 10% quarter-over-quarter to $177M.

Based on Omega Fund Management's 13F filing for Q3 2017, filed 3 Nov 2017.